82 related articles for article (PubMed ID: 6889915)
1. Response of the Dunning R3327H prostatic adenocarcinoma to radiation and various chemotherapeutic drugs.
Mador D; Ritchie B; Meeker B; Moore R; Elliott FG; McPhee MS; Chapman JD; Lakey WH
Cancer Treat Rep; 1982 Oct; 66(10):1837-43. PubMed ID: 6889915
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer.
Smolev JK; Heston WD; Scott WW; Coffey DS
Cancer Treat Rep; 1977; 61(2):273-87. PubMed ID: 872132
[TBL] [Abstract][Full Text] [Related]
3. Systematic investigation into interaction of ionizing radiation and doxorubicin in the Dunning R3327G prostatic adenocarcinoma model.
Gottlieb CF; Seibert GB; Block NL
NCI Monogr; 1988; (6):147-53. PubMed ID: 3352758
[TBL] [Abstract][Full Text] [Related]
4. Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
Abramjuk C; Lein M; Rothaug W; Krell HW; Loening SA; Jung K
Cancer Chemother Pharmacol; 2007 Feb; 59(2):275-82. PubMed ID: 16758188
[TBL] [Abstract][Full Text] [Related]
5. [Potentiation of focal ultrasound treatment of prostate adenocarcinoma by concomitant chemotherapy with estramustine phosphate and paclitaxel].
Paparel P; Chapelon JY; Curiel L; Rabilloud M; Chesnais S; Gelet A
Prog Urol; 2004 Feb; 14(1):40-6. PubMed ID: 15098750
[TBL] [Abstract][Full Text] [Related]
6. The effects of castration, testosterone and oestrogen on epithelial and stromal growth and morphology of the Dunning (R3327H) prostatic adenocarcinoma.
Damber JE; Landström M; Bergh A; Tomic R
Scand J Urol Nephrol Suppl; 1988; 110():145-8. PubMed ID: 3187402
[No Abstract] [Full Text] [Related]
7. Endocrine manipulation of the Dunning prostatic adenocarcinoma.
Shessel FS; Block NL; Stover B; Claflin A; Malinin TI; Politano VA
Invest Urol; 1980 May; 17(6):529-33. PubMed ID: 7372443
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
[TBL] [Abstract][Full Text] [Related]
9. Purification and characterization of acid phosphatase from Dunning R3327H prostatic adenocarcinoma.
Lee C; Murphy GP; Chu TM
Cancer Res; 1980 Apr; 40(4):1245-8. PubMed ID: 7357554
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
Getzenberg RH; Light BW; Lapco PE; Konety BR; Nangia AK; Acierno JS; Dhir R; Shurin Z; Day RS; Trump DL; Johnson CS
Urology; 1997 Dec; 50(6):999-1006. PubMed ID: 9426741
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of a cloned cell line R3327H-G8-A1 derived from the dunning R3327H rat adenocarcinoma.
Sestili MA; Norris JS; Smith RG
Cancer Res; 1983 May; 43(5):2167-75. PubMed ID: 6299542
[TBL] [Abstract][Full Text] [Related]
13. Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor.
Lokeshwar BL; Hurkadli KS; Sheth AR; Block NL
Cancer Res; 1993 Oct; 53(20):4855-9. PubMed ID: 8402673
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity.
Vujaskovic Z; Feng QF; Rabbani ZN; Samulski TV; Anscher MS; Brizel DM
Exp Lung Res; 2002; 28(7):577-90. PubMed ID: 12396250
[TBL] [Abstract][Full Text] [Related]
15. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
16. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
[TBL] [Abstract][Full Text] [Related]
17. The Nb rat prostatic adenocarcinoma model system.
Drago JR; Goldman LB; Maurer RE
Prog Clin Biol Res; 1980; 37():265-91. PubMed ID: 7384086
[TBL] [Abstract][Full Text] [Related]
18. Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model.
Johannsen M; Thiesen B; Jordan A; Taymoorian K; Gneveckow U; Waldöfner N; Scholz R; Koch M; Lein M; Jung K; Loening SA
Prostate; 2005 Aug; 64(3):283-92. PubMed ID: 15726645
[TBL] [Abstract][Full Text] [Related]
19. Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth.
Hautmann SH; Huland E; Huland H
Anticancer Res; 1999; 19(4A):2661-3. PubMed ID: 10470215
[TBL] [Abstract][Full Text] [Related]
20. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
Koppan M; Nagy A; Schally AV; Arencibia JM; Plonowski A; Halmos G
Cancer Res; 1998 Sep; 58(18):4132-7. PubMed ID: 9751625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
